v3.26.1
Discontinuation of M6 product lines
6 Months Ended
Jun. 30, 2026
Discontinuation of Product Line and Held for Sale Assets [Abstract]  
Discontinuation of M6 product lines

15. Discontinuation of M6 product lines

In February 2025, the Company announced the discontinuation of its M6-C artificial cervical disc and M6-L artificial lumbar disc product lines (together, the "M6 artificial discs" or "M6 product lines") in order to allocate associated resources and investment to more profitable growth opportunities. Financial results for the Company's M6 product lines continue to be presented within the Company's consolidated statements of operations and comprehensive loss. A summary of impairment charges recognized during the three and six months ended June 30, 2025, and the associated financial statement lines in which such costs were recognized is shown in the table below. All such changes are included within the Company's Global Spine reporting segment. All related inventory; property, plant, and equipment; and intangible asset balances were fully impaired in the prior year; therefore, there were no further impairments recorded on these assets in the current year.

(Unaudited, U.S. Dollars, in thousands)

Financial Statement Line Item

Three Months Ended June 30, 2025

 

 

Six Months Ended June 30, 2025

 

Inventory reserve charges

Cost of sales

$

2,548

 

 

$

11,251

 

Impairment of property, plant, and equipment

Operating expenses

 

608

 

 

 

6,834

 

Impairment of developed technology intangible asset

Acquisition-related amortization, impairment, and remeasurement

 

 

 

 

14,097

 

Loss on M6 inventories and long-lived assets held for sale

$

3,156

 

 

$

32,182